by MM360 Staff | Jun 10, 2021 | Publications
Lancet Haematol. 2021 Jun;8(6):e422-e432. doi: 10.1016/S2352-3026(21)00130-7.ABSTRACTBackground Lenalidomide maintenance improves progression-free survival for patients with multiple myeloma, although its optimal duration is unknown. Clearance of minimal residual...
by MM360 Staff | Jun 10, 2021 | Publications
Lancet Haematol. 2021 Jun;8(6):e446-e461. doi: 10.1016/S2352-3026(21)00057-0.ABSTRACTChimeric antigen receptors (CAR) are fusion proteins containing an antigen-recognition domain coupled to a T-cell activation domain (eg, CD3ζ [CD247]) and to a costimulatory domain...
by MM360 Staff | Jun 10, 2021 | Twitter
Excellent presentation by Faith Davis @ASCO on HRMM➡️55% affected MM cells as cutoff to determine significance of del17➡️highest risk in patients with del17p and mutations 17p in remaining allel➡️functional HR if PFS is less than 18 mos #mmsm #ASCO21 #myeloma...
by MM360 Staff | Jun 10, 2021 | Twitter
#ASCO21 Tuesday 8AM EST ➡️Plasma Cell Dyscrasia Session ➡️Please join me and my colleague @PLMcCarthyMD for fantastic presentations on #myeloma with @profBigG @Ccostello7 @szusmani @NBahlis @DoctorAKrishnan @BerdejaJesus @SurbhiSidanaMD https://t.co/Iny6YvtqUc—...
by MM360 Staff | Jun 10, 2021 | Twitter
CONGRESS | #ASCO21 | @BerdejaJesus presents the updated results of the MonumenTAL-1 trial, evaluating talquetamab, a novel bsAb targeting GPRC5D/CD3, in heavily pretreated patients with RRMM #mmsm @SarahCannonDocs pic.twitter.com/fFyXdM3tMq— Multiple Myeloma Hub...
